CN101493463A - 胃癌诊断试剂及其用途 - Google Patents
胃癌诊断试剂及其用途 Download PDFInfo
- Publication number
- CN101493463A CN101493463A CNA2008100330171A CN200810033017A CN101493463A CN 101493463 A CN101493463 A CN 101493463A CN A2008100330171 A CNA2008100330171 A CN A2008100330171A CN 200810033017 A CN200810033017 A CN 200810033017A CN 101493463 A CN101493463 A CN 101493463A
- Authority
- CN
- China
- Prior art keywords
- antibody
- stomach cancer
- reagent box
- cancer diagnosis
- diagnosis reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 70
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 58
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 58
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 47
- 238000003745 diagnosis Methods 0.000 claims abstract description 41
- 239000007790 solid phase Substances 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 108090001008 Avidin Proteins 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 7
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 claims description 6
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 4
- 150000002602 lanthanoids Chemical class 0.000 claims description 4
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 239000007788 liquid Substances 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 abstract 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 201000000498 stomach carcinoma Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- MTNQLAKBYRCDTF-UHFFFAOYSA-N (2-nitrophenyl)phosphonic acid Chemical compound OP(O)(=O)C1=CC=CC=C1[N+]([O-])=O MTNQLAKBYRCDTF-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-M 2-nitrophenolate Chemical compound [O-]C1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-M 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HEVGGTGPGPKZHF-UHFFFAOYSA-N Epilaurene Natural products CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 206010034647 Peristalsis visible Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000022534 visible peristalsis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810033017 CN101493463B (zh) | 2008-01-24 | 2008-01-24 | 胃癌诊断试剂及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810033017 CN101493463B (zh) | 2008-01-24 | 2008-01-24 | 胃癌诊断试剂及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101493463A true CN101493463A (zh) | 2009-07-29 |
CN101493463B CN101493463B (zh) | 2013-05-29 |
Family
ID=40924163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810033017 Active CN101493463B (zh) | 2008-01-24 | 2008-01-24 | 胃癌诊断试剂及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101493463B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102680706A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 蛋白质ctsf在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
CN102680687A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 蛋白质terf1在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
CN102680688A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 |
WO2014146487A1 (zh) * | 2013-03-20 | 2014-09-25 | 上海麦柏星生物科技有限公司 | 抗细胞表面异位表达的单克隆抗体及其制备方法和用途 |
CN109564225A (zh) * | 2016-08-09 | 2019-04-02 | B.R.A.H.M.S 有限公司 | 作为指示不良事件的标志物的组蛋白和/或proADM |
-
2008
- 2008-01-24 CN CN 200810033017 patent/CN101493463B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102680706A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 蛋白质ctsf在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
CN102680687A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 蛋白质terf1在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
CN102680688A (zh) * | 2012-05-14 | 2012-09-19 | 上海交通大学 | 诊断试剂盒及bfar在制备胃癌早期诊断试剂中的应用 |
CN102680706B (zh) * | 2012-05-14 | 2014-07-02 | 上海交通大学 | 蛋白质ctsf在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
CN102680687B (zh) * | 2012-05-14 | 2014-12-24 | 上海交通大学 | 蛋白质terf1在制备诊断胃癌的试剂中的应用及诊断试剂盒 |
WO2014146487A1 (zh) * | 2013-03-20 | 2014-09-25 | 上海麦柏星生物科技有限公司 | 抗细胞表面异位表达的单克隆抗体及其制备方法和用途 |
CN109564225A (zh) * | 2016-08-09 | 2019-04-02 | B.R.A.H.M.S 有限公司 | 作为指示不良事件的标志物的组蛋白和/或proADM |
Also Published As
Publication number | Publication date |
---|---|
CN101493463B (zh) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mian et al. | Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder | |
CN104136630B (zh) | 诊断和预示乳腺癌的标志物 | |
TWI698639B (zh) | 前列腺抗原標準品及其用途 | |
CN101493463B (zh) | 胃癌诊断试剂及其用途 | |
US12013406B2 (en) | Methods of detecting anti-folic acid antibodies and uses thereof | |
CN110187109A (zh) | 一种用于贲门腺癌早期筛查的自身抗体联合检测elisa试剂盒 | |
CN102043058A (zh) | 用于预测肿瘤的乙酰金刚烷胺的检测试剂盒 | |
WO2016195051A1 (ja) | 膵がんを診断するための血漿バイオマーカーパネル | |
CN106680515B (zh) | 用于肺癌诊断的多分子标志物组合 | |
CN110187111B (zh) | 一种用于早期贲门癌筛查elisa试剂盒 | |
CN109425740A (zh) | 异常凝血酶原(pivka-ⅱ)磁微粒化学发光免疫分析测定试剂盒及其制备方法 | |
CN104105791A (zh) | 诊断和预示肠癌的标志物 | |
CN111505300B (zh) | 一种早期食管癌联合筛查试纸条 | |
CN109116023A (zh) | 一种肺癌标志物抗-mmp12自身抗体及其应用 | |
US4578349A (en) | Immunoassay for carcinoembryonic antigen (CEA) | |
US6649420B1 (en) | Methods and devices for detecting no-complexed prostate specific I antigen | |
CN115372616A (zh) | 胃癌相关的生物标志物及其应用 | |
CN111323588B (zh) | 食管癌相关抗原蛋白组合或其特异性抗体在食管癌检测试剂盒中的应用 | |
US20150004633A1 (en) | Assays and methods for the diagnosis of ovarian cancer | |
US5955287A (en) | Method of determining level of biological substances elevated in the presence of cancer and other neoplasms | |
US10866238B2 (en) | Alpha methylacyl a coenzyme racemase detection | |
EP2129688A2 (en) | Compositions and methods for detecting cancers in a subject | |
KR102649112B1 (ko) | 인간의 소변을 검체로 이용하여 대장암을 진단하는 진단키트 | |
CN111239398B (zh) | 一种血清ethe1蛋白自身抗体检测的方法 | |
US20230400466A1 (en) | Methods and systems for risk stratification and management of bladder cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI JINGYUAN INVESTMENT CO., LTD. Free format text: FORMER OWNER: RUIJIN HOSPITAL ATTACHED TO MEDICAL COLLEGE OF SHANGHAI JIAOTONG UNIV. Effective date: 20150910 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150910 Address after: 201103 room 1506, Nick building, 528 Xu Hong Road, Shanghai, Minhang District Patentee after: Shanghai Jingyuan Investment Co.,Ltd. Address before: 200025 Luwan District Road, Ruijin, No. two, No. 197, Shanghai Patentee before: RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG University SCHOOL OF MEDICINE |